Ovarian Cancer and Us - best viewed in FIREFOX

Search: this blog, links from posts and the web.....

Loading...

Friday, February 06, 2009

Trial Offers Early Test Case for Personalized Medicine - JNCI Journal of the National Cancer Institute



Trial Offers Early Test Case for Personalized Medicine -- Garber 101 (3): 136 -- JNCI Journal of the National Cancer Institute

Editorial: Predictors of Referral for Psychosocial Services: Recommendations From the Institute of Medicine Report--Cancer Care for the Whole Patient



Predictors of Referral for Psychosocial Services: Recommendations From the Institute of Medicine Report--Cancer Care for the Whole Patient -- Alter 27 (5): 659 -- Journal of Clinical Oncology

Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes



Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes

globeandmail.com: Breast cancer risk, HRT link confirmed - Comments



globeandmail.com: Breast cancer risk, HRT link confirmed - Comments

(S Pniauskas, from Canada) wrote: Most of these unresolved issues stem from the well know publication of the WHI study (Women's Health Initiative). It is important to view this related research as it applies to oneself and in conjunction with a knowledgeable health care provider. The WHI publication authors acknowledged the media events were damaging and did not adequately relay pertinent or clear information to neither the consumer/public nor health care providers - so a lesson not well learned.
Further, there is a significant population of women for whom the WHI did not address which includes pre-menopausal women and those surgically and/or treatment-related induced menopause. For these women, and in particular, for those with surgically induced menopause, a one-size fits all - does not. There are significant differences between natural menopause and surgically/treatment-related menopause.

This Future Medicine editorial may be of interest:
http://tinyurl.com/cmgxek

HRT/ERT/MRT is an area of concern not only to breast cancer women (those at risk of whom there are many) but also those genetically predisposed to breast, ovarian, uterine (endometrial) and colo-rectal women.

A blanket statement on definitve implications is impossible at the moment. While some criticize the many post analyses in sub-groups of the WHI, it is necessary due to the often critical and criticized absences of important information that was not included in the WHI.

June 2007: Current Management Strategies for Ovarian Cancer — Mayo Clinic Proceedings



Current Management Strategies for Ovarian Cancer — Mayo Clinic Proceedings